PAK vs WI: Pakistan and West Indies are set to clash in their last Test series of the World Test Championship 2025 cycle in Multan starting on January 17. Both teams enter this two-match series ...

YARDLEY, Pa., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced ...

"Our preliminary unaudited fourth quarter net product revenue of $22.4 million is in line with our prior guidance and demonstrates a sustained growth in XHANCE prescriptions through the fourth ...

(RTTNews) - Optinose, Inc. (OPTN), a pharmaceutical company focused on ear, nose and throat or ENT and allergy, announced Wednesday preliminary XHANCE (fluticasone propionate) net product revenue ...

Optinose reports preliminary fourth quarter 2024 XHANCE revenue of $22.4 million, indicating sustained prescription growth. Full results expected in March. Optinose, a pharmaceutical company ...

YARDLEY, Pa. - Optinose (NASDAQ:OPTN), a pharmaceutical company specializing in treatments for ear, nose, and throat (ENT) and allergy care, announced today a preliminary unaudited net product revenue ...

(MENAFN- GlobeNewsWire - Nasdaq) Preliminary XHANCE prescription growth rate from third quarter to fourth quarter 2024 estimated to be approximately 20% YARDLEY, Pa., Jan. 15, 2025 (GLOBE NEWSWIRE ...

This figure aligns with the company's previous guidance and reflects a continued increase in XHANCE prescriptions during the quarter. According to CEO Ramy Mahmoud, the company experienced an ...

“Our preliminary unaudited fourth quarter net product revenue of $22.4 million is in line with our prior guidance and demonstrates a sustained growth in XHANCE prescriptions through the fourth ...